Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06617481 · ClinicalTrials.gov registry record · Phase 2
PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
A Phase 2 study of Prostate Cancer (Post Prostatectomy), sponsored by AdventHealth.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06617481: Recruiting Phase 2 study of Prostate Cancer (Post Prostatectomy), sponsored by AdventHealth.
NCT06617481 is a Phase 2 study of Prostate Cancer (Post Prostatectomy) that is actively recruiting participants, run by AdventHealth. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06617481, a Phase 2 study of Prostate Cancer (Post Prostatectomy), is actively recruiting participants, sponsored by AdventHealth.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer. The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.
Primary Outcome
Patients who undergo at least one rhPSMA-7.3 (18F) PET-scan will be analyzed for the primary endpoint. The malignant lesion detectability rate will be summarized using percentage and 95% confidence interval estimates overall and for those who underwent a single scan or both scans. The diagnostic evaluation aims to identify individuals who are most likely to have an isolated local relapse, as they have the most significant potential for achieving long-term disease control through additional local
Conditions Studied
Interventions
- DRUG 18F-rhPSMA-7.3 (Posluma)
Study Locations (1)
Florida
- AdventHealth - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-09-20 |
| Est. Completion | 2027-10-10 |
| Phase | Phase 2 |
What NCT06617481 shows while recruiting
NCT06617481 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Prostate Cancer (Post Prostatectomy) appearing as the primary indexed condition, and to 1 intervention - of which 18F-rhPSMA-7.3 (Posluma) is the first listed.
NCT06617481 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06617481 about?
NCT06617481 is a clinical study titled "PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence". Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer. The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when the...
What is the current status of trial NCT06617481?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2024-09-20. Estimated completion is 2027-10-10.
What conditions does trial NCT06617481 study?
This clinical trial studies the following conditions: Prostate Cancer (Post Prostatectomy).
What interventions are being tested in trial NCT06617481?
The interventions under investigation include: 18F-rhPSMA-7.3 (Posluma) (DRUG).
Who is sponsoring clinical trial NCT06617481?
This trial is sponsored by AdventHealth, which has 95 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06617481 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer (Post Prostatectomy)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06617481's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI